The most common treatments for osteoporosis are bisphosphonates, monoclonal receptor activator of nuclear factor-kB ligand (RANKL) antibodies, monoclonal sclerostin antibodies, and a parathyroid hormone peptide.72 The parathyroid hormone peptide increases osteoblast activity and inhibits osteoclast recruitment, whereas the targets of the other treatments inhibit osteoclast resorption.73 However, these treatments have limitations and problems with side effects and serious risks. This evidence concerns the gene SOST and osteoporosis.